



ONE TECHNOLOGY. MULTIPLE MARKETS.

BROADER LIGHT PROTECTION.

Rise Nano Optics is advancing SPECTRAGUARD™, a patented nano-particle lens treatment engineered to selectively filter high-energy light while preserving visual clarity. The platform is designed for performance, consumer and clinical eyewear applications.

THE GLOBAL EYEWEAR AND EYECARE
MARKET IS ESTIMATED AT

US\$160 BILLION

AND EXPECTED TO GROW TO US\$330 BILLION
BY 2034

! THE PROBLEM

Traditional eyewear is largely designed around UV protection. That leaves gaps across visible high-energy light, glare and light sensitivity.

- Screen-heavy lifestyles increase exposure
- Specialty lens options remain fragmented
- Patients with light sensitivity need better support
- Clinical applications remain underserved

Eye protection needs a broader standard.

SG OUR SOLUTION

SPECTRAGUARD™ integrates nano-particles into the lens substrate to selectively filter problematic wavelengths while maintaining natural visual clarity.

- Filters up to 90% from 400–600 nm
- Provides 100% UV protection
- Designed not to scratch or wear off
- Photochromic and outdoor configurations

Broader protection. Natural visual clarity.

↗ WHY NOW

Regulatory progress and a partner-led model position Rise to move from product validation toward commercial scale.

- FDA Class I exempt registration
- First optical laboratory signed
- Global labs and manufacturers in discussion
- North American commercialization strategy

The platform is ready for commercialization.


INVESTMENT HIGHLIGHTS

- 1 Patented nano-material and lens-treatment IP
- 2 Large and growing global market
- 3 Capital-efficient partner and licensing model
- 4 FDA Class I exempt device registration
- 5 Experienced leadership and board
- 6 Canadian-listed company with strong governance

KEY MILESTONES

- 2014 Initial US patent granted
- 2024 Lens-diffusion patents granted
- 2025 Additional US IP issued / filed
- Q1 2026 CSE listing under EYE
- MAR 2026 FDA Class I exempt registration
- MAY 2026 First lab signed
- NEXT Scale partnerships and launch

PROPOSED USE OF PROCEEDS



CAPITAL PROGRAM: TO BE CONFIRMED

Indicative allocation for management review only.

EXPERIENCED LEADERSHIP



Dr. Inas Said
Founder & CEO



Erik Ritchie
Chief Commercial
Officer



Dr. Awad Shalabny
Chief Technology
Officer



Gabi Kabazo
Chief Financial Officer

STRONG BOARD OVERSIGHT

B

Independent directors with expertise in optics, technology, finance and governance.

WHY ISRAEL. WHY CANADA.

☆

ISRAEL INNOVATION

Nanomaterials expertise, Technion research and a world-class innovation ecosystem.

CA

CANADIAN ADVANTAGE

Access to North American capital markets with strong governance and transparency.

NEXT STEPS

Engaging a select group of institutional investors, family offices and strategic partners in Canada and the United States.



To arrange a confidential discussion or request more information:
John C. Sinclair, CPA | Director
Investor contact: ir@risenanooptics.com